Literature DB >> 23249919

Biceps skin-fold thickness may detect and predict early lipoatrophy in HIV-infected children.

Steve Innes1, Eva Schulte-Kemna, Mark F Cotton, Ekkehard Werner Zöllner, Richard Haubrich, Hartwig Klinker, Xiaoying Sun, Sonia Jain, Clair Edson, Margaret van Niekerk, Emily Ryan Innes, Helena Rabie, Sara H Browne.   

Abstract

BACKGROUND: The prevalence of potentially stigmatizing lipoatrophy in children receiving antiretroviral therapy in Southern Africa is high, affecting around a third of children. Early diagnosis of lipoatrophy is essential for effective intervention to arrest progression.
METHODS: Prepubertal children receiving antiretroviral therapy were recruited from a hospital-based family HIV clinic in Cape Town and followed up prospectively. Lipoatrophy was identified and graded by consensus between 2 HIV pediatricians. A dietician performed anthropometric measurements of trunk and limb fat. Anthropometric measurements in children with and without lipoatrophy were compared using multivariable linear regression adjusting for age and gender. The most discerning anthropometric indicators of lipoatrophy underwent receiver operating characteristic curve analysis. The precision of anthropometric measurements performed by an inexperienced healthcare worker was compared with that of a research dietician.
RESULTS: Of 100 recruits, 36 had lipoatrophy at baseline and a further 9 developed lipoatrophy by 15-month follow-up. Annual incidence of lipoatrophy was 12% (confidence interval [CI]: 5-20%) per person-year of follow-up. A biceps skin-fold thickness <5 mm at baseline had a sensitivity of 89% (CI: 67-100%) and a specificity of 60% (CI: 46-75%) for predicting development of lipoatrophy by 15-month follow-up. Negative and positive predictive values were 97% (CI: 91-100%) and 32% (CI: 14-50%).
CONCLUSION: Biceps skin-fold thickness <5 mm in prepubertal children exposed to thymidine analogue-based antiretroviral therapy may be a useful screening tool to identify children who are likely to develop lipoatrophy. The variation in precision of measurements performed by an inexperienced healthcare worker only marginally impacted performance.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23249919      PMCID: PMC4000309          DOI: 10.1097/INF.0b013e3182814b30

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  26 in total

1.  Recovery from lipodystrophy in HIV-infected children after substitution of stavudine with zidovudine in a non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.

Authors:  Linda Aurpibul; Thanyawee Puthanakit; Sineenart Taejaroenkul; Thira Sirisanthana; Virat Sirisanthana
Journal:  Pediatr Infect Dis J       Date:  2012-04       Impact factor: 2.129

2.  Analyzing a portion of the ROC curve.

Authors:  D K McClish
Journal:  Med Decis Making       Date:  1989 Jul-Sep       Impact factor: 2.583

3.  Static and dynamic differences among five types of skinfold calipers.

Authors:  P K Schmidt; J E Carter
Journal:  Hum Biol       Date:  1990-06       Impact factor: 0.553

4.  Weight and skinfold variation at menarche and the critical body weight hypothesis.

Authors:  N Cameron
Journal:  Ann Hum Biol       Date:  1976-05       Impact factor: 1.533

5.  Longitudinal evaluation and risk factors of lipodystrophy and associated metabolic changes in HIV-infected children.

Authors:  Marta Beregszaszi; Catherine Dollfus; Martine Levine; Albert Faye; Samia Deghmoun; Nassima Bellal; Muriel Houang; Didier Chevenne; Régis Hankard; Jean-Louis Bresson; Stéphane Blanche; Claire Levy-Marchal
Journal:  J Acquir Immune Defic Syndr       Date:  2005-10-01       Impact factor: 3.731

6.  An objective case definition of lipodystrophy in HIV-infected adults: a case-control study.

Authors:  A Carr; S Emery; M Law; R Puls; J D Lundgren; W G Powderly
Journal:  Lancet       Date:  2003-03-01       Impact factor: 79.321

7.  Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe.

Authors: 
Journal:  AIDS       Date:  2004-07-02       Impact factor: 4.177

8.  Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial.

Authors:  Andrew Carr; Cassy Workman; Don E Smith; Jennifer Hoy; Jeff Hudson; Nicholas Doong; Allison Martin; Janaki Amin; Judith Freund; Matthew Law; David A Cooper
Journal:  JAMA       Date:  2002-07-10       Impact factor: 56.272

9.  Body fat abnormality in HIV-infected children and adolescents living in Europe: prevalence and risk factors.

Authors:  Naufil Alam; Mario Cortina-Borja; Tessa Goetghebuer; Magdalena Marczynska; Alessandra Vigano; Claire Thorne
Journal:  J Acquir Immune Defic Syndr       Date:  2012-03-01       Impact factor: 3.731

10.  High prevalence of lipoatrophy in pre-pubertal South African children on antiretroviral therapy: a cross-sectional study.

Authors:  Steve Innes; Mark F Cotton; Richard Haubrich; Maria M Conradie; Margaret van Niekerk; Clair Edson; Helena Rabie; Sonia Jain; Xiaoying Sun; Ekkehard W Zöllner; Stephen Hough; Sara H Browne
Journal:  BMC Pediatr       Date:  2012-11-23       Impact factor: 2.125

View more
  2 in total

1.  A Randomized Comparison of Anthropomorphic Changes With Preferred and Alternative Efavirenz-Based Antiretroviral Regimens in Diverse Multinational Settings.

Authors:  Kristine M Erlandson; Sineenart Taejaroenkul; Laura Smeaton; Amita Gupta; Isaac L Singini; Javier R Lama; Rosie Mngqibisa; Cynthia Firnhaber; Sandra Wagner Cardoso; Cecilia Kanyama; Andre L Machado da Silva; James G Hakim; Nagalingeswaran Kumarasamy; Thomas B Campbell; Michael D Hughes
Journal:  Open Forum Infect Dis       Date:  2015-06-24       Impact factor: 3.835

2.  Lipoatrophy/lipohypertrophy outcomes after antiretroviral therapy switch in children in the UK/Ireland.

Authors:  Steve Innes; Justin Harvey; Intira Jeannie Collins; Mark Fredric Cotton; Ali Judd
Journal:  PLoS One       Date:  2018-04-04       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.